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ABSTRACT
Objectives: To investigate the impact of
depression and its treatment on health-related
quality of life (HRQoL) in a naturalistic, primary
care setting in the UK.
Methods: The Factors Influencing Depression
Endpoints Research (FINDER) study was a
European, 6-month, prospective, observational
study designed to estimate HRQoL in patients
with a clinical diagnosis of depression. This
paper examines primary care patients recruited
in the UK. HRQoL was measured at baseline and
at 3 and 6 months after starting antidepressant
therapy using the Short Form 36 Health Status
Survey and the European Quality of Life-5
Dimensions (EQ-5D). Regression analysis was
used to identify baseline and treatment
variables independently and significantly
associated with HRQoL. Further analyses
included the effect of caseness for depression
on HRQoL, the effect of moderate/severe pain at
baseline on HRQoL, changes in overall pain,
pain interference scores, and the use of different
antidepressants by pain cohort.
Results: A total of 608 patients was recruited
from 58 centres and mean HRQoL was
significantly below reported population norms
at baseline. Most improvement in HRQoL was
seen at 3 months for EQ-5D, with small
additional improvement at 6 months. Worse
HRQoL outcomes at 6 months were associated
with higher somatic symptoms score, duration
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of depression at baseline, and switching within
antidepressant classes. Patients meeting the
criteria for caseness for depression, or with
significant pain at baseline showed less
improvement in HRQoL scores at 6 months.
Conclusion: Patients presenting with
depression in primary care show reduced
HRQoL compared to population norms.
HRQoL improves during antidepressant
treatment particularly within the first
3 months. Nonpainful somatic symptoms,
socioeconomic factors, depression variables
and switching within antidepressant class
predict poor HRQoL outcome. Pain is a
common symptom in depressed patients and
remains after 6 months’ treatment. Pain and
somatic symptoms should be assessed in all
patients with depression in primary care.
Keywords: Antidepressant; Depression; Pain;
Primary care; Quality of life
INTRODUCTION
The concept of health was defined by the World
Health Organization in 1948 as ‘‘a state of
complete physical, mental and social well-
being and not merely the absence of disease
or infirmity’’ [1]. This was later refined into
five dimensions of health-related quality of
life (HRQoL) encompassing physical, social,
psychological, overall life satisfaction/
wellbeing and perceptions of health status at
the 1993 International Consensus Conference
[2]. HRQoL is used to assess both functional
outcome and quality of life (QoL) across disease
states and has been demonstrated to be
impaired in depressed patients compared to
both the general population and to people with
chronic medical conditions such as diabetes,
arthritis, and heart disease [3–5]. It is therefore
important to understand what factors influence
HRQoL in depression and how these influence
response to treatment. The five dimensions of
HRQoL can be assessed using tools such as the
Short Form 36 Health Status Survey (SF-36) [6]
and European Quality of Life-5 Dimensions
(EQ-5D) [7] and although studies have
previously assessed the effectiveness of
antidepressant treatments on HRQoL [8–13]
further research is needed in order to improve
our understanding of factors related to HRQoL
and its improvement during treatment. Two
possible moderators of HRQoL in depression are
somatic and pain symptoms. Many depressed
patients present with somatic symptoms [14]
and there is a strong association between
depression and painful symptoms in primary
care [15]. It is known that painful symptoms
adversely affect treatment outcomes in
depression [16], but less is known about their
impact on HRQoL outcomes.
The European Factors Influencing
Depression Endpoints Research (FINDER)
observational study [17–19] was designed to
increase understanding of the factors that
influence HRQoL outcomes for clinically
depressed outpatients receiving antidepressant
medication in routine primary and secondary
care. In this study, pain and its impact on
functioning were also assessed using patient-
reported measures. A strength of this study is
that it included patients with other chronic
medical comorbidities that may influence
HRQoL and outcomes, and so is more
reflective of the clinical populations found in
primary care than those from randomized
controlled trials in which greater use of
exclusion criteria is normal. The findings from
naturalistic observational studies such as
FINDER may therefore be generalizable to a
larger population and can be used to provide
direction for further research [20].
26 Neurol Ther (2013) 2:25–42
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The primary objective of this paper is to
estimate the HRQoL of a primary care depressed
population at baseline (untreated) and 3 and
6 months after initiation of antidepressant
treatment. A shared secondary objective was to
determine the factors associated with HRQoL at
baseline and 6 months. Additional, post hoc
secondary objectives specific to the UK sample
were: to describe the impact of caseness for
depression at baseline on HRQoL; to describe
the impact of pain (explained medical cause/
unexplained medical cause) at baseline on
HRQoL; to describe changes in overall pain
and pain interference outcomes by pain cohort
(explained medical cause/unexplained medical
cause); and to summarize antidepressant use
by pain cohort (explained medical cause/
unexplained medical cause).
The authors are not aware of any other paper
which has sought to bring together outcomes as
measured by QoL with the factors that influence
outcomes as described above, making this an




The UK subset of the FINDER study was
designed as a prospective, noninterventional,
observational study to measure QoL in patients
diagnosed as having depressive disorder by their
general practitioner (GP) and initiated on
antidepressants. The results of the full
European study have already been published
elsewhere [17–19]. Here, the authors report the
study design and findings from the UK cohort of
patients only. The study was approved by the
Eastern Multicentre Research Ethics Committee
in Cambridge. Subsequent to clinical diagnosis
and the decision to treat with an antidepressant,
patients gave written informed consent for the
provision and collection of data during the
observation period.
Patient Sample and Data Collection
Patients based in primary care were enrolled by
participating investigators between May 2004
and September 2005 if they: presented within
the normal course of care for depression and
were clinically diagnosed with depression by
their GP; were about to receive pharmacological
treatment for either their first episode of
depression or for a new episode of depression;
were at least 18 years of age; and were not
simultaneously participating in a different
study that included an investigational drug or
procedure. The choice of pharmacological
treatment was determined solely at the
discretion of each participating physician in
agreement with the patient.
Data collection for the study took place
during routine visits to the patient’s GP. There
were three data collection time points: at
baseline, when the patient was prescribed
pharmacological treatment for a new or first
episode of depression; at 3 (±1) months post
baseline; and at 6 (±1) months post baseline.
Baseline data collected included patient
sociodemographics, psychiatric history, duration
of the current depressive episode, and the presence
of comorbid chronic medical conditions and
functional syndromes. Antidepressants
prescribed were recorded and subsequently
grouped as follows: selective serotonin reuptake
inhibitors (SSRIs), serotonin noradrenaline
reuptake inhibitors (SNRIs), tricyclic
antidepressants (TCAs), others (including herbal
remedies, lithium,monoamineoxidase inhibitors),
or combinations of antidepressants.
Neurol Ther (2013) 2:25–42 27
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Measures
HRQoL was completed by the patient using the
two components of the SF-36 [SF-36 version 2.0:
mental components summary (MCS), which
includes vitality, social functioning, role-
emotional and mental health scales, and
physical components summary (PCS), which
includes physical functioning, role-physical,
bodily pain, and general health scales] [6] and
the EQ-5D [7].
The Hospital Anxiety and Depression Scale
[HADS; subscales HADS-A (anxiety) and HADS-
D (depression)] [21] was used by patients to self-
rate symptoms of anxiety and depression. As
patients were diagnosed with depression based
on the clinical judgment of the investigator
rather than with a recognized diagnostic tool,
the HADS was used to define a case of probable
depression. Caseness for depression was defined
as a score of 8 or greater on HADS-D, which has
high sensitivity and specificity for detecting a
major depressive episode (0.80 and 0.88,
respectively) in a GP setting [22].
Somatic symptoms were assessed using the
28-item Somatic Symptom Inventory (SSI-28)
[23], consisting of seven pain-related items (SSI-
pain) and 21 items not relating to pain (SSI-
somatic).
Overall pain severity and the impact of pain
on daily functioning during the past week were
rated by patients at each visit using a visual
analog score (VAS; 0–100). For overall pain
severity, ratings of 30 mm or less were
categorized as no/mild pain and over 30 mm
were considered to be moderate/severe pain
[24].
Sample Size
A target sample size of 600 patients was
determined for the original, UK-only study
based on the primary objective of determining
the QoL of a depressed population before
treatment and at 3 and 6 months after
treatment had started using the two summaries
of SF-36: the MCS and the PCS. According to a
SF-36 user manual [25], the mean (SD) MCS and
PCS for a clinically depressed population (in the
US) are 34.84 (12.17) and 44.96 (12.05),
respectively. For the normal population, the
mean (SD) is 50 (10) for both MCS and PCS.
Assuming a SD of approximately 12 with 600
patients, the 95% confidence limits around the
mean were calculated to be ±0.96 for both the
MCS and PCS.
Statistical Analysis
Descriptive statistics were calculated for each
variable for all patients eligible for analysis at
baseline; only those patients with data from at
least one follow-up visit were included in the
regression analyses.
HRQoL and Independent Variables
The baseline analysis of HRQoL used linear
regression analysis to identify independent
variables associated with HRQoL; a mixed-
effects model repeated measures analysis with
unstructured covariance structure was used for
the longitudinal analyses. Backward regression
methods were used to identify variables
independently associated with HRQoL
outcomes. Separate models were fitted for each
of the following outcome variables: SF-36 (MCS,
PCS), EQ-5D [VAS and health status index (HSI)].
Independent variables were removed from the
full model until only statistically significant
(P B 0.05) variables remained. The independent
variables included in the initial model were: age,
gender, education (none/mandatory, further),
occupation status (working for pay,
unemployed, other), marital status (married/
domestic partner, other), body mass index,
28 Neurol Ther (2013) 2:25–42
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number of dependants, smoking (yes, no),
number of previous episodes of depression, age
at first episode, any psychiatric illness in the
24 months before baseline (yes, no), any
functional syndromes (yes, no), duration of
current depressive episode, HADS-A score,
HADS-D score, SSI-somatic score, and pain
cohort (no/mild pain, explained pain,
unexplained pain). Also included in the
longitudinal analysis were: class of
antidepressant taken between 3 and 6 months,
switch (between, within, none) between
antidepressants taken between baseline and
3 months and between 3 and 6 months, and
baseline value of the dependent variable.
HRQoL and the Effect of ‘‘Caseness’’
of Depression
HRQoL scores are divided into two depression
subgroups: cases of depression and noncases of
depression, as defined at baseline by the HADS-
D score. A score of 8 or greater indicates a case of
depression, whereas a score of less than 8
indicates a noncase.
HRQoL and the Effect of Pain
Three pain subgroups are described: those with
no or mild pain; those with moderate/severe
pain with a defined medical disorder known to
cause pain as based on physician selection of
listed comorbidities (termed explained pain);
and those with moderate/severe pain with a
defined medical disorder not associated with
pain or without further comorbidity other than
depression (termed unexplained pain). Pain was
assessed in the study using the overall pain VAS,
in which a score of 0–30 represented no/mild
pain and a score over 30 represented moderate/
severe pain. For HRQoL and VAS pain scores in
the overall sample and in the three pain
cohorts, if the 95% two-sided confidence
intervals (CI) for the means at two time points
or for two cohorts did not overlap, the
difference was considered statistically
significant as this procedure corresponds to a
conservative two-sided test at the 5% level.
RESULTS
A total of 608 patients was enrolled in the study
in the UK by 58 participating doctors, of whom
57 were GPs.
Patient Characteristics at Baseline
The baseline characteristics of eligible patients
are summarized in Table 1. A total of 35% had a
history of depressive episodes in the previous
2 years (excluding the index episode), and
anxiety/panic disorder (29%) was the most
common psychiatric illness experienced in the
24 months before baseline. At baseline, 34% of
patients had at least one comorbid, chronic,
physical condition and 19% had a comorbid
functional syndrome (19%). The most
common comorbid physical conditions were
hypertension (13%) and asthma (11%), and the
most common comorbid functional syndrome
was irritable bowel syndrome (10%). At
baseline, 82% of patients met the criteria for a
case of depression (HADS-D score C8). At the
baseline visit, 68% of patients had not received
an antidepressant in the previous 24 months,
21% had received SSRIs only, 1% TCAs only, 5%
other drugs only, and 5% combinations of
antidepressants.
Health-Related Quality of Life
Figure 1 [25, 26] shows the mean [standard
deviation (SD)] SF-36 scores (MCS and PCS) and
mean (SD) EQ-5D scores (VAS and HSI) at
baseline, 3 and 6 months. At baseline SF-36
(MCS), EQ-5D VAS and EQ-5D HSI scores were
Neurol Ther (2013) 2:25–42 29
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significantly below general population norms.
There were improvements in HRQoL (except
SF-36 PCS) at 3 months with further small
improvements at 6 months.
The independent variables significantly
associated with HRQoL at baseline are
summarized in Table 2 and include SSI-somatic
score, HADS-D, HADS-A, presence of moderate to
severe pain, gender, occupational status, and age.
The independent variables significantly
associated with changes in HRQoL from
baseline to 6 months are shown in Table 3.
Numerous factors were associated with a worse
HRQoL outcome: a higher SSI-somatic score at
baseline, socioeconomic factors (older age, being
unemployed, being married), depression
variables (higher HADS-D score at baseline,
more previous episodes of depression, longer
duration of current depressive episode), previous
psychiatric illness, comorbid functional
syndromes, and treatment switching within
antidepressant class during the 6-month
treatment period. Factors associated with a
better HRQoL outcome include female gender,
older age at first episode, and higher HRQoL
scores at baseline.
HRQoL by Caseness for Depression
Figure 2 [25, 26] presents the mean HRQoL
results (SF-36 MCS and PCS, EQ-5D VAS and
HSI) by caseness for depression (baseline HADS-
D score C8 indicates a case of depression). Cases
of depression were associated with lower mean
HRQoL scores at all time points, compared with
noncases. There were increases in the mean
SF-36 MCS and EQ-5D scores during treatment
in both cases and noncases of depression. SF-36
PCS scores were within one SD (10) of the
population norm at baseline and during the
course of treatment for both cases and noncases.
HRQoL by Pain Cohort
Figure 3 [25, 26] presents the mean HRQoL
results by pain cohort. Patients with pain
(explained pain and unexplained pain) had
lower mean scores for SF-36 PCS and EQ-5D
(HSI and VAS) at all three time points than
patients with no/mild pain. Notably, the mean
PCS scores remained at or below clinical
depression norms even after 6 months of
treatment in the two groups with pain.
Table 1 Baseline characteristics of patients (n = 608)
Variable % or mean – SD
Age (years) 42.8 ± 14.7
Women 61.2
Body mass index (kg/m2) 26.9 ± 6.2
Duration of depression (years) 5.3 ± 8.3
History of depressive episodes
in previous 24 months
(excluding index episode)
34.6





in previous 24 monthsa
Anxiety/panic disorder 28.7








SD standard deviation, VAS visual analog scale
a Reported if greater than 4%. Examples below this
threshold include schizophrenia and bipolar disorder
b Pain severity was rated by patients on a 100 mm VAS in
which 0 = no pain and 100 = pain as severe as I can
imagine
c Overall pain VAS B30
d Overall pain VAS[30
30 Neurol Ther (2013) 2:25–42
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Pain Outcomes
The mean pain VAS for all patients at baseline was
34.1 (95% CI 31.8–36.3). This decreased to 29.9
(95% CI 27.3–32.5) at 3 months and to 27.1 (95%
CI 24.4–29.9) at 6 months; the decrease from
baseline to6 monthswas considered significantas
the 95% CIs did not overlap. The decrease from
baseline was not significant at 3 months.
Table 4 shows the VAS scores for overall pain
and interference of pain with ability to perform
daily activities by pain cohort at baseline, 3 and
6 months.
The mean overall pain VAS (i.e., pain
severity) was significantly reduced from
baseline at 3 and 6 months in both the
explained and unexplained pain cohorts. Mean
VAS scores for interference of pain with ability
to do daily activities were reduced from baseline
at 3 and 6 months for both the explained and
unexplained pain cohorts, indicating that pain
interfered less with patients’ ability to do daily
activities. This change was significant for the
unexplained pain group only.
Treatment Patterns by Pain Cohort
Figure 4 presents the antidepressant use
patterns for the first and second 3 months of
treatment in the three pain cohorts (no/mild
Fig. 1 Mean (SD) SF-36 and EQ-5D scores at baseline, 3
and 6 months. SF-36 MCS and PCS scores were normal-
ized to a mean of 50 (SD 10). The solid line represents the
SF-36 general US population norm (mean 50) and the
dotted line represents the clinical depression norms (MCS
mean 34.8; PCS mean 45.0) [25]. Mean EQ-5D HSI scores
were converted from a 0–1 scale to a 0–100 scale. The solid
line represents the UK general population norms (EQ-5D
VAS mean 82.5; EQ-5D HSI mean 86) [26]. EQ-5D
European Quality of Life-5 Dimensions, HSI health status
index, HRQoL health-related quality of life, MCS mental
component summary, PCS physical component summary,
SD standard deviation, SF-36 Short Form 36 Health Status
Survey, VAS visual analog scale
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pain, explained pain, and unexplained pain) as
defined at baseline. Note, this is actual use of
medication during 0–3 months and 3–6 months
as reported by patients, not the medication
prescribed at the baseline and 3-month visits,
respectively. SSRIs were the most commonly
used antidepressants irrespective of pain
symptoms, although during the second
3 months of observation there was a decrease
in their use that was highest in the explained
pain cohort.
Prescribing patterns were very similar for the
cohorts with no/mild pain and unexplained
pain suggesting little differential prescribing
based on the presence of painful symptoms. It
is also interesting to note that during the
second 3 months of treatment, 15–22% of
patients reported not using any antidepressants.
DISCUSSION
The results of this study found that HRQoL (as
measured by the SF-36 and EQ-5D) in patients
with a first or new episode of depression
presenting in UK primary care was below that
previously reported in healthy populations.
HRQoL improved during the first 3 months
following antidepressant initiation, with more
Fig. 2 Mean HRQoL scores at baseline, 3 and 6 months by
caseness for depression (based on HADS-D score at
baseline: score C8 = case; score \8 = noncase). SF-36
MCS and PCS scores were normalized to a mean of 50 (SD
10). The solid line represents the SF-36 general US
population norm (mean 50) and the dotted line represents
the clinical depression norms (MCS mean 34.8; PCS mean
45.0) [25]. Mean EQ-5D HSI scores were converted from a
0–1 scale to a 0–100 scale. The solid line represents the UK
general population norms (EQ-5D VAS mean 82.5;
EQ-5DHSImean 86) [26]. EQ-5D EuropeanQuality of Life-5
Dimensions, HADS-D Hospital Anxiety and Depression
Scale-depression, HSI health status index, HRQoL health-
related quality of life, MCS mental component summary,
PCS physical component summary, SD standard deviation,
SF-36 Short Form 36 Health Status Survey, VAS visual
analog scale
34 Neurol Ther (2013) 2:25–42
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limited improvement from 3 to 6 months. The
findings of this study in UK primary care patients
are therefore similar to those of the full European
FINDER study with respect to the primary
objective. Similarly, the SF-36 MCS score at the
end of the study had not normalized (50) and was
at least1SDlower thanfor thegeneralpopulation.
The study also showed minimal change on SF-36
PCS, probably reflecting a ceiling effect as a mean
score of 50 represents the score for the general
population. These results are consistent with
other clinical studies [8–13].
The independent variables significantly
associated with HRQoL at baseline in the UK
sample include SSI-somatic score, HADS-D,
HADS-A, pain cohort, gender, occupational
status, and age. Patients with adverse
sociodemographics, greater general medical
and depressive illness burden have been
identified with poorer QoL [27]. The authors’
finding that a higher SSI-somatic score was
associated with a poorer HRQoL supports
previous findings of an inverse relationship
between somatic symptoms and QoL [28].
Moreover, a recent cross-sectional study in a
large population of primary care patients with
depression showed that numerous
characteristics of somatic symptoms (number,
Fig. 3 Mean HRQoL scores at baseline, 3 and 6 months by
pain cohort. SF-36 MCS and PCS scores were normalized
to a mean of 50 (SD 10). The solid line represents the SF-
36 general US population norm (mean 50) and the dotted
line represents the clinical depression norms (MCS mean
34.8; PCS mean 45.0) [25]. Mean EQ-5D HSI scores were
converted from a 0–1 scale to a 0–100 scale. The solid line
represents the UK general population norms (EQ-5D VAS
mean 82.5; EQ-5D HSI mean 86) [26]. EQ-5D European
Quality of Life-5 Dimensions, EX/P explained pain, HSI
health status index, HRQoL health-related quality of life,
MCS mental component summary, N/MP no/mild pain,
PCS physical component summary, SD standard deviation,
SF-36 Short Form 36 Health Status Survey, UNEX/P
unexplained pain, VAS visual analog scale
Neurol Ther (2013) 2:25–42 35
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disability, persistence) were associated with a
decreased QoL [29].
Higher SSI-somatic scores were also
associated with worse HRQoL outcomes over
time, highlighting the continuing impact of
(nonpainful) somatic symptoms on HRQoL.
Somatic symptoms have been found to be
associated with pain and improvement in pain
outcomes in the European cohort of the FINDER
study [30]. As the presence of painful symptoms
has been shown to compromise outcomes of
antidepressant treatment [16, 31], so the results
of this study suggest that nonpainful physical
symptoms as well as painful symptoms should
be taken into account when maximizing
treatment response in depression.
An important finding was that those patients
who switched antidepressant treatment within
the same antidepressant class (e.g., SSRI) had a
poorer HRQoL (SF-36 MCS, EQ-5D health state
value) outcome over the 6-month follow-up
period than those who had no change in
treatment or who switched to a different
antidepressant class. Switching between
antidepressant classes (e.g., SSRI to SNRI) was
not significantly associated with poorer HRQoL
outcome. These findings suggest that if a
change in treatment is necessary, it may be
more advantageous in terms of HRQoL to
switch from one antidepressant class to
another. This should be explored in more
detail in a controlled setting.
The association of sociodemographic and
depression-related factors with changes in
HRQoL remain consistent with the European
analysis [19]. Pain cohort (no pain or either
explained or unexplained pain) was not
significantly associated with change in HRQoL
in the UK sample, despite significant results in
the univariate analysis and an association with
baseline HRQoL. Pain was associated with worse
HRQoL (SF-36 MCS only) in the European
analysis (P = 0.026) using the overall pain VAS
score rather than pain cohorts [19]. It is likely
Table 4 VAS scores for pain at baseline, 3, and 6 months by pain cohort
No/mild pain Explained pain Unexplained pain
n Mean (95% CI) n Mean (95% CI) n Mean (95% CI)
Overall paina
Baseline 297 9.5 (8.4–10.6) 65 62.3 (57.9–66.6) 239 57.0 (54.8–59.2)
3 months 216 16.2 (13.3–19.1) 46 46.0 (38.0–53.9) 173 42.4 (38.4–46.4)
6 months 192 14.8 (12.2–17.4) 43 48.0 (38.6–57.3) 155 36.4 (31.6–41.2)
Interference with daily activitiesb
Baseline 296 12.8 (10.5–15.0) 65 60.7 (53.0–68.4) 239 53.9 (50.2–57.6)
3 months 215 12.5 (9.7–15.2) 46 45.6 (35.9–55.2) 174 36.4 (31.8–41.1)
6 months 192 10.2 (7.8–12.7) 43 44.1 (33.3–55.0) 155 33.9 (28.5–39.3)
No/mild pain was deﬁned as an overall pain VAS B30 at baseline; both the explained and unexplained pain groups had an
overall pain VAS[30 at baseline
CI conﬁdence interval, VAS visual analog scale
a Overall pain severity was rated by patients on a 100 mm VAS in which 0 = no pain and 100 = pain as severe as I can
imagine
b Interference of overall pain with ability to perform daily activities was rated by patients on a 100 mm VAS with 0 = not
at all to 100 = complete
36 Neurol Ther (2013) 2:25–42
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that lack of sensitivity of the pain cohort
compared to that of the pain VAS score, in
addition to the smaller sample size in the UK,
account for this discrepancy.
Only a few previous studies have used EQ-5D
to assess HRQoL in depressed patients in
primary care [13, 32, 33]. In a naturalistic,
longitudinal, primary care study in Sweden [33],
the EQ-5D VAS scores at baseline (40) and after
6 months of antidepressant treatment (63) were
similar to those found in the present study (47
and 68, respectively, at baseline and 6 months).
The same was true for the EQ-5D health state
values. Nevertheless, despite improvement
during 6 months of follow-up, the mean EQ-
5D scores in the present study remained below
the European population norms by almost 1 SD
[26].
Using the patient-rated HADS-D score of 8 or
greater as a cut-off due to high sensitivity and
specificity in general practice [22], the majority
of patients (82%) recruited into the UK FINDER
study met the criteria for caseness for
depression. This supports the view that UK
GPs involved with this study were good at
diagnosing clinical depression. The baseline
mean SF-36 summary scores (MCS 19.2 and
PCS 47.4) for patients who met the criteria for
caseness correspond closely to the mean values
reported in a French primary care study [32] of
patients with major depressive disorder defined
by the Diagnostic and Statistical Manual of
Mental Disorders, IVth revision (MCS 21.1 and
PCS 43.6).
The reduction in pain severity (measured
using the overall pain VAS) for the whole
Fig. 4 Antidepressant use in the ﬁrst 3 months
(0–3 months) and second 3 months (3–6 months) of
treatment by pain cohort. Clinically signiﬁcant pain was
deﬁned as overall pain VAS greater than 30 mm at baseline.
SNRI serotonin noradrenaline reuptake inhibitor, SSRI
selective serotonin reuptake inhibitor, TCA tricyclic anti-
depressant, VAS visual analog scale
Neurol Ther (2013) 2:25–42 37
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patient cohort was only statistically significant at
the 6-month post baseline assessment. However,
when patients with no/mild pain were separated
from those with moderate/severe pain, there
were significant reductions in the overall pain
VAS score at both 3 and 6 months in patients
with medically explained and those with
unexplained pain, which exceeded the 12 mm
threshold for a minimum clinically significant
difference reported by Kelly [34]. Despite the
above finding, the cohort with unexplained pain
at baseline still had moderate pain at the end of
the study (mean overall pain VAS 36.4).
Furthermore, pain interference with daily
activities was still significantly impaired in the
unexplained pain cohort compared with the no/
mild pain cohort (mean VAS 33.9 vs. 10.2). This
observation suggests that by 6 months, the
antidepressant treatments that were given in
the study (which were mainly SSRIs) were neither
very effective at treating the painful somatic
symptoms in depression nor at minimising the
associated disability.
Antidepressant use patterns in this UK
general practice study were in accordance with
the National Institute for Health and Clinical
Excellence guidelines for depression [35], which
were published halfway through recruitment
into this study (May 2004 to September 2005);
the majority of patients received SSRIs as first-
line treatment. The pattern of antidepressant
use was similar for patients with unexplained
pain and without pain, in contrast to the
explained pain cohort, in which TCAs were
more commonly used in the first 3 months and
combination therapy in the second 3 months.
This lack of differentiation indicates that GPs
either do not take pain into account when
selecting antidepressants for depressed patients
when there is no comorbid medical condition
present or feel that using different classes of
antidepressant would not be of value.
This study supports the view that different
antidepressant strategies may be required to
reduce both disability and residual pain
symptoms to normal values in the management
of depressed patients with painful somatic
symptoms. A recent Sequenced Treatment
Alternatives to Relieve Depression (STAR-D)
report [36] focusing on poorer treatment
outcome with an SSRI when painful physical
symptoms are present reinforces this point.
Furthermore, assessment and treatment of
depression in primary care should incorporate
pain measurement. This could be encouraged in
the UK by the adoption of pain assessment in the
mental health section of the quality and
outcomes framework [37] that provides
voluntary targets to GPs with financial incentives.
Research into the association of painful
symptoms of depression and poorer HRQoL
outcome warrants further investigation in a
controlled setting, in longer studies, and using
different treatment modalities including
comparisonsofdifferent classes of antidepressant.
The most significant strength of the study is
that it is one of the largest prospective,
observational studies of HRQoL during
treatment for depression in a primary care
setting. It reflects the reality of prescribing and
outcomes in UK general practice over a
6-month time period. Furthermore, the use of
robust validated measures exploring depression
caseness, HRQoL and pain add to the existing
literature and can help inform clinical practice
and future research.
The study has several limitations in addition
to those common to observational studies due
to the lack of randomization, such as selection
and observer bias. First, the observation period
was limited to 6 months, so it is unclear if
HRQoL would become comparable to
population norms with further treatment, or if
a deficit would remain for those with pain on
38 Neurol Ther (2013) 2:25–42
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current treatment. Conversely, due to the
episodic nature of depression, it is possible
that improvement in depression and related
HRQoL in some subjects over the 6-month
period represents the natural course of the
illness rather than improvement related to any
treatment given. Furthermore, without a
control group, improvement could represent
regression towards the mean. Second, during
the second 3-month period of the study,
15–22% of patients in each group were not
receiving drug treatment, and it is unclear how
this may have affected HRQoL outcome overall
and in the different pain cohorts. Finally, the
results do not reflect the complete spectrum of
patients presenting with depression in primary
care, but those in whom mutual agreement
between clinician and patient has resulted in a
course of antidepressants. The ThREshold for
AntiDepressant response (THREAD) study [38]
conducted in UK general practice found that
many patients, albeit with mild to moderate
depression, declined to receive antidepressants.
The UK GP patients in this study, in contrast
with the mixed primary and secondary care
populations of the European FINDER study [17],
presented with a shorter history of depression:
mean duration of depression (5.3 vs. 8.5 years),
mean number of depressive episodes (1.3 vs. 1.8)
in the previous 24-month period for those with
at least one previous episode, and a less frequent
history of anxiety/panic disorder (28.7% vs.
51.1%) in the previous 24-month period.
CONCLUSION
Patients who present with depression in
primary care in the UK have a poor QoL,
which improves markedly in the first
3 months of treatment. There are several
variables associated with a poor HRQoL
outcome, notably somatic symptoms
(nonpainful), socioeconomic and depression
factors, and switching within antidepressant
class. The presence of pain with either a
known or unknown cause is common, remains
clinically significant, and is associated with
poor QoL outcome at baseline, but is not
predictive of it at 6 months. Nonpainful
somatic symptoms are associated with HRQoL
and pain outcomes over the treatment period.
Therefore, although the relationship is
complex, pain and nonpainful somatic
symptoms should be assessed and monitored
in all patients with depression in primary care.
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